Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size

Journal of Nuclear Medicine

Bert F. Bernard¹  Eric P. Krenning¹  Willem H. Bakker¹  Wout A.P. Breeman¹  Theo J. Visser¹  Peter P.M. Kooij¹  Arthur van Gameren¹  Marion de Jong¹ 

[1] Departments of Nuclear Medicine and Internal Medicine III, University Hospital and Erasmus University Rotterdam, Rotterdam, The Netherlands Departments of Nuclear Medicine and Internal Medicine III, University Hospital and Erasmus University Rotterdam, Rotterdam, The Netherlands Departments of Nuclear Medicine and Internal Medicine III, University Hospital and Erasmus University Rotterdam, Rotterdam, The Netherlands

关键词: [⁹⁰Y-DOTA⁰;    Tyr³]octreotide;    peptide receptor radionuclide therapy;    rat;    tumor size;    curability;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

A promising application of radiolabeled somatostatin analogs is peptide receptor–targeted radionuclide therapy of somatostatin receptor–expressing tumors. A suitable radionuclide is 90Y, which emits high-energy β-particles with a pathlength of several millimeters in tissue, making it especially promising for treatment of large tumors. Methods: We investigated the radiotherapeutic effect of different activities (111 and 370 MBq) of [90Y-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA)0,Tyr3]octreotide in Lewis rats bearing somatostatin receptor–positive rat pancreatic CA20948 tumors of different size (0.08–15 cm2) in their flank. Results: Dose-dependent radiotherapeutic effects of 90Y-labeled octreotide in this rat tumor model were found. Tumor control (100% complete response) was found in animals bearing tumors of 3–9 cm2 (mean, 7.8 cm2) after intravenous injection of the highest activity (370 MBq [90Y-DOTA0,Tyr3]octreotide). In rats bearing tumors of ≤1 cm2 or ≥14 cm2, the effects were less pronounced (50% and 0% complete response, respectively). In tumors of ≤1 cm2 the 90Y radiation energy will not be absorbed completely in the tumor, whereas in tumors of ≥14 cm2 the increased number of clonogenic and probably hypoxic tumor cells may explain the failure to reach a cure. Conclusion: This study shows the ability of [90Y-DOTA0,Tyr3]octreotide to control tumor growth, especially in medium-sized tumors. The effect of radionuclide therapy appeared to be dependent on tumor size at the onset of therapy.

【 授权许可】

Unknown